Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid strategies after denosumab discontinuation in postmenopausal osteoporosis
2024-511871-13-00Phase 4Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of zoledronic acid in postmenopausal osteoporosis (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Primary composite endpoint: lumbar BMD maintenance or vertebral fracture at 1 year. Planned start Nov 2024; status: authorised.
02
Drugs
zoledronic acid
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2024-511871-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511871-13-00.